



HAL
open science

Correction to: Measuring Treatment Effect on Psoriatic Arthritis-Related Domains: Insights from the SPIRIT-H2H Study at Weeks 24 and 52

Frank Behrens, Soyi Liu Leage, Christophe Sapin, Celine El Baou, Inmaculada de la Torre, Gabriella Meszaros, Georg Schett, Bernard Combe, Filip van Den Bosch, Laure Gossec

► To cite this version:

Frank Behrens, Soyi Liu Leage, Christophe Sapin, Celine El Baou, Inmaculada de la Torre, et al.. Correction to: Measuring Treatment Effect on Psoriatic Arthritis-Related Domains: Insights from the SPIRIT-H2H Study at Weeks 24 and 52. *Clinical Rheumatology*, 2021, 40 (12), pp.4955–4956. 10.1007/s10067-021-05966-3 . hal-03892145

HAL Id: hal-03892145

<https://hal.sorbonne-universite.fr/hal-03892145>

Submitted on 30 Apr 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Correction to: Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52

Frank Behrens¹ · Soyi Liu Leage² · Christophe Sapin² · Celine El Baou² · Inmaculada De La Torre² · Gabriella Meszaros² · Georg Schett^{3,4} · Bernard Combe⁵ · Filip van den Bosch⁶ · Laure Gossec^{7,8}

Published online: 4 November 2021
© The Author(s) 2021

Correction to: Clinical Rheumatology

<https://doi.org/10.1007/s10067-021-05891-5>

In the original published version of this article, the Figure 4 contained error. The line “ACR50 plus PASI100” has been presented incorrectly. The Figure 4 is now presented correctly.

The original article has been corrected.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s10067-021-05891-5>

✉ Frank Behrens
frank.behrens@ime.fraunhofer.de

¹ Dpt. of Rheumatology, Goethe University and Fraunhofer ITMP and CIMD, 60590 Frankfurt am Main, Germany

² Eli Lilly and Company, Indianapolis, USA

³ Friedrich-Alexander-University Erlangen-Nuremberg and Universitätsklinikum, Erlangen, Germany


⁴ Deutsches Zentrum Für Immuntherapie, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

⁵ Montpellier University, Montpellier, France

⁶ Ghent University Hospital, Ghent, Belgium

⁷ Sorbonne Université, INSERM, Institut Pierre Louis D'Epidémiologie Et de Santé Publique, Paris, France

⁸ Rheumatology Department, Pitié-Salpêtrière Hospital, AP-HP Sorbonne Université, Paris, France



	Response group at week 52, n (%) ^b				
	CR52 (ACR50 plus PASI100) (N=185)	JR52 (ACR50 only) (N=97)	SR52 (PASI100 only) (N=114)	Neither ACR50 nor PASI 100 (N=83)	Discontinued (N=87)
ACR50 plus PASI100	116 (62.7)	14 (14.4)	29 (25.4)	5 (6.0)	17 (19.5)
ACR50 only	24 (13.0)	50 (51.5)	6 (5.3)	9 (10.8)	5 (5.7)
PASI100 only	28 (15.1)	4 (4.1)	57 (50.0)	19 (22.9)	13 (14.9)
Neither ACR50 nor PASI100	17 (9.2)	29 (29.9)	22 (19.3)	50 (60.2)	52 (59.8)

^aNeither ACR50 nor PASI100. ^bThe Sankey diagram and tabulated patient numbers show the numbers and proportions of each week 52 response group who had the response specified on the left at week 24. The four response groups were Combined Responder (CR52): patients who achieved simultaneous ACR50 and PASI100 response, Joint Responder (JR52): patients who achieved ACR50 but not PASI100 response, Skin Responder (SR52): patients who achieved PASI100 but not ACR50 response, and Non-responder (NR52): patients who did not achieve ACR50 or PASI100 response after 52 weeks of treatment. ACR50: improvement of $\geq 50\%$ in American College of Rheumatology criteria; CR52: combined responder at week 52; JR52: joint responder at week 52; ITT: intention to treat; NR52: non-responder at week 52; PASI100: 100% improvement in Psoriasis Area Severity Index score; SR52: skin responder at week 52

Fig. 4 Sankey diagram showing trajectory of response based on response group at week 52